ROCO
4166
Market cap200mUSD
May 19, Last price
32.35TWD
1D
-0.31%
1Q
-16.19%
Jan 2017
10.79%
IPO
-35.31%
Name
Orient Pharma Co Ltd
Chart & Performance
P/E
56.34
P/S
4.95
EPS
0.57
Div Yield, %
—
Shrs. gr., 5y
7.47%
Rev. gr., 5y
28.17%
Revenues
1.22b
+37.41%
Net income
107m
+381.76%
CFO
197m
P
Profile
Orient Pharma Co., Ltd. engages in the research and development, manufacturing, and sales of drugs in Taiwan and internationally. The company develops anti-psychotics and psychostimulants, as well as drugs for treating Parkinson's and Alzheimer's diseases; and products for the treatment of sialorrhea, tuberculosis, and attention deficit hyperactivity disorder. It is also developing drug delivery technologies, such as multi-stages-controlled release technology, trans-dermal patches, oral disintegrating tablets, sustained release technology, and micro granules. The company was founded in 2008 and is based in Taipei, Taiwan.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | 1,222,816 37.41% | 889,912 73.86% | 511,859 10.47% | |||
Cost of revenue | 1,048,906 | 862,159 | 553,595 | |||
Unusual Expense (Income) | ||||||
NOPBT | 173,910 | 27,753 | (41,736) | |||
NOPBT Margin | 14.22% | 3.12% | ||||
Operating Taxes | 55,749 | 636 | (12,348) | |||
Tax Rate | 32.06% | 2.29% | ||||
NOPAT | 118,161 | 27,117 | (29,388) | |||
Net income | 107,374 381.76% | 22,288 -177.50% | (28,759) -71.98% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | 308,733 | 393,193 | 107,559 | |||
Long-term debt | 452,441 | 553,360 | 637,433 | |||
Deferred revenue | ||||||
Other long-term liabilities | 5,857 | 5,094 | 5,942 | |||
Net debt | 663,030 | 861,356 | 665,510 | |||
| Cash flow | ||||||
Cash from operating activities | 197,014 | (102,993) | 11,384 | |||
CAPEX | (27,332) | (54,109) | (28,920) | |||
Cash from investing activities | (22,475) | (88,015) | (29,085) | |||
Cash from financing activities | (173,363) | 197,897 | (36,794) | |||
FCF | 62,308 | (220,924) | (137,003) | |||
| Balance | ||||||
Cash | 109,295 | 113,119 | 97,230 | |||
Long term investments | (11,151) | (27,922) | (17,748) | |||
Excess cash | 37,003 | 40,701 | 53,889 | |||
Stockholders' equity | 651,209 | 540,164 | 160,663 | |||
Invested Capital | 2,303,222 | 2,351,812 | 1,550,188 | |||
ROIC | 5.08% | 1.39% | ||||
ROCE | 7.43% | 1.16% | ||||
| EV | ||||||
Common stock shares outstanding | 223,696 | 223,035 | 187,003 | |||
Price | 36.00 81.36% | 19.85 -4.80% | 20.85 12.70% | |||
Market cap | 8,053,050 81.90% | 4,427,245 13.55% | 3,899,013 12.70% | |||
EV | 8,716,080 | 5,288,601 | 4,567,411 | |||
EBITDA | 309,631 | 163,324 | 27,364 | |||
EV/EBITDA | 28.15 | 32.38 | 166.91 | |||
Interest | 13,968 | 13,900 | 7,374 | |||
Interest/NOPBT | 8.03% | 50.08% | ||||